Inhibition of T cell activation and autoimmune diabetes using a B cell surface–linked CTLA-4 agonist
J. Clin. Invest. Brian T. Fife, et al. 116:2252 doi:10.1172/JCI27856 [Go to this article.]

Figure 3
In vitro activation of B cells and T cells from scαCTLA-4 Tg⁺ mice. (A) B and T cell proliferation was assessed from scαCTLA-4 Tg⁺ and controls using splenocytes following 0, 0.1, 1, or 10 μg/ml (A) anti-IgM, (B) LPS, or (C) anti-CD3 stimulation. (D) Flow cytometric analysis from scαCTLA-4 Tg⁺ and FVB controls after 48-hour culture with anti-IgM (1 μg/ml). Shaded histogram represents positive stain for B7-1, B7-2, CD40, and MHC II. Percentage positive above isotype control with mean fluorescence intensity (ΔMFI) is shown. Histograms are gated on B220⁺ cells. Data presented are representative of 3 independent experiments with ≥ 3 mice per group.